True Diagnostics

Executive Summary

True Diagnostics is a San Diego-based point-of-care and over-the-counter diagnostics company founded in 2015. The company has developed the proprietary TrueDX platform, which delivers lab-quality qualitative and quantitative results from small samples (blood, urine, or saliva) within minutes. True Diagnostics targets the prevention, diagnosis, and treatment of various medical conditions, with a focus on expanding access to rapid testing. The company's stage is marked as "Approved," suggesting it has received regulatory clearance for at least one product, and it operates in the competitive diagnostics sector. True Diagnostics is positioned to capitalize on the growing demand for decentralized testing, driven by consumer preference for convenience and speed. With its TrueDX platform, the company can address multiple applications, from infectious diseases to chronic condition monitoring. While specific financials and commercial traction are not publicly available, the company's regulatory approval status and innovative platform provide a foundation for growth. Key risks include competition from established diagnostics players and the need for continued innovation to maintain differentiation. Overall, True Diagnostics represents a speculative opportunity in the diagnostics space, contingent on successful product launches and market adoption.

Upcoming Catalysts (preview)

• Q4 2026FDA clearance for a new quantitative infectious disease test70% success
• Q1 2027Distribution partnership with a national pharmacy chain for OTC tests60% success
• Q3 2026Launch of a home-use respiratory panel (COVID/Flu/RSV) test50% success